WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Jeffrey C. Bank
Partner
Antitrust and Competition
Washington, D.C.
jbank@wsgr.com

D212-497-7761

Download vCard
Open PDF
  • A Strategic Partner

    Jeff serves as a strategic partner to clients in their most significant matters, identifying cost-effective strategies to secure favorable outcomes.

  • Key Industry Experience

    Jeff has represented companies in antitrust litigation and counseling matters, particularly those in the pharmaceutical, healthcare, technology, manufacturing, and media industries.

  • A Recognized Practictioner

    Jeff was recognized as a 2020 “Rising Star” in antitrust by Law360, in Bloomberg Law’s inaugural “40 Under 40" in 2021, and as a “Future Leader” in 2021-2024 and a 2024 “Global Elite Thought Leader” by Global Competition Review/Who’s Who.

Jeff Bank is a partner and co-chair of the antitrust litigation group at Wilson Sonsini Goodrich & Rosati. Jeff currently serves as a member of the firm’s board of directors.

As a seasoned litigator representing both plaintiffs and defendants, Jeff has handled a wide range of complex matters, from multi-district litigations and global cartel cases to actions against competitors. He has successfully defended pharmaceutical, technology, manufacturing, and media companies against class actions and has extensive experience in all aspects of litigation, from discovery through appeal. In the 2022 edition of Who's Who Legal - Competition, Jeff was recognized as a “thoughtful and strategic litigator” who provides “very strong client-orientated service."

In addition to his litigation practice, Jeff regularly advises clients on business practices, government investigations, and merger clearance issues, and has represented a broad array of clients before federal and state agencies.

Jeff has successfully guided clients on all types of competition matters, including those related to monopolization, price-fixing, AI tools and pricing algorithms, exclusive dealing, and unfair competition. Jeff has also advised companies in a wide variety of industries and jurisdictions on compliance-related issues and has helped develop cutting-edge compliance programs for global and domestic entities. In addition, Jeff helps clients identify cost-effective strategies to overcome anticompetitive practices by competitors, and he has recovered hundreds of millions of dollars and regulatory relief on behalf of those clients. 

Prior to joining the firm, Jeff practiced at the Federal Trade Commission's Health Care Division, where he focused on competition issues in the pharmaceutical and healthcare industry.

Beyond his antitrust practice, Jeff is deeply committed to pro bono work. He currently serves on the firm’s Pro Bono Committee and has worked on numerous immigration and asylum matters. He was honored with the John Wilson Award, which is presented annually to individual attorneys who have demonstrated a significant commitment to the firm's pro bono clients. Jeff is also the board president of Spoons Across America, a New York-based nonprofit.

Experience

Jeff Bank is a partner and co-chair of the antitrust litigation group at Wilson Sonsini Goodrich & Rosati. Jeff currently serves as a member of the firm’s board of directors.

As a seasoned litigator representing both plaintiffs and defendants, Jeff has handled a wide range of complex matters, from multi-district litigations and global cartel cases to actions against competitors. He has successfully defended pharmaceutical, technology, manufacturing, and media companies against class actions and has extensive experience in all aspects of litigation, from discovery through appeal. In the 2022 edition of Who's Who Legal - Competition, Jeff was recognized as a “thoughtful and strategic litigator” who provides “very strong client-orientated service."

In addition to his litigation practice, Jeff regularly advises clients on business practices, government investigations, and merger clearance issues, and has represented a broad array of clients before federal and state agencies.

Jeff has successfully guided clients on all types of competition matters, including those related to monopolization, price-fixing, AI tools and pricing algorithms, exclusive dealing, and unfair competition. Jeff has also advised companies in a wide variety of industries and jurisdictions on compliance-related issues and has helped develop cutting-edge compliance programs for global and domestic entities. In addition, Jeff helps clients identify cost-effective strategies to overcome anticompetitive practices by competitors, and he has recovered hundreds of millions of dollars and regulatory relief on behalf of those clients. 

Prior to joining the firm, Jeff practiced at the Federal Trade Commission's Health Care Division, where he focused on competition issues in the pharmaceutical and healthcare industry.

Beyond his antitrust practice, Jeff is deeply committed to pro bono work. He currently serves on the firm’s Pro Bono Committee and has worked on numerous immigration and asylum matters. He was honored with the John Wilson Award, which is presented annually to individual attorneys who have demonstrated a significant commitment to the firm's pro bono clients. Jeff is also the board president of Spoons Across America, a New York-based nonprofit.

Education
  • J.D., Cornell Law School, 2006Editor, International Law Journal
  • B.S., Cornell University, School of Industrial and Labor Relations, 2003
Honors
  • Recognized in the D.C. Antitrust: Litigation Specialists category in the 2026 edition of Chambers USA
  • Recognized in the 2025-2026 editions of Lawdragon's "500 Leading Global Antitrust & Competition Lawyers"
  • Named a “Stand-out Lawyer” by Thomson Reuters in 2025 and 2026
  • Named among Washingtonian’s 2024 Top Lawyers
  • Recognized in the 2025 edition of GCR/Lexology Index's Competition guide
  • Named a “Future Leader” in 2021-2024 and a 2024 “Global Elite Thought Leader” by GCR/Who’s Who Legal: Competition
Admissions
  • Bar of the District of Columbia
  • State Bar of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Appeals for the First Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Ninth Circuit
Credentials
Education
  • J.D., Cornell Law School, 2006Editor, International Law Journal
  • B.S., Cornell University, School of Industrial and Labor Relations, 2003
Honors
  • Recognized in the D.C. Antitrust: Litigation Specialists category in the 2026 edition of Chambers USA
  • Recognized in the 2025-2026 editions of Lawdragon's "500 Leading Global Antitrust & Competition Lawyers"
  • Named a “Stand-out Lawyer” by Thomson Reuters in 2025 and 2026
  • Named among Washingtonian’s 2024 Top Lawyers
  • Recognized in the 2025 edition of GCR/Lexology Index's Competition guide
  • Named a “Future Leader” in 2021-2024 and a 2024 “Global Elite Thought Leader” by GCR/Who’s Who Legal: Competition
Admissions
  • Bar of the District of Columbia
  • State Bar of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Appeals for the First Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Ninth Circuit

Representative Matters

  • Defending Mylan Inc. against price-fixing and market allocation claims in one of the largest multi-district litigations, In re Generic Pharmaceuticals, brought by private class and non-class plaintiffs as well as dozens of State AGs.
  • Defending multi-family apartment owner/operator in In re RealPage, cutting-edge litigation brought by putative class of renters regarding algorithmic pricing software.
  • Defending former CEO of healthcare company in alleged no-poach case brought by putative class of employees, In re Outpatient.
  • Defending specialty pharmaceutical manufacturer in alleged sham litigation matter brought by generic competitor.
  • Defending electronic technology company against California unfair competition claim brought by competitor.
  • Defending global tire manufacturer against price-fixing claims brought by putative classes of purchasers in In re Replacement Tires.
  • Defending news agency company against collusion claims.
  • Representing pharmaceutical manufacturers in connection with reverse payment litigations, and obtained dismissals in other such litigations.
  • Successfully resolved price-fixing claims against Hitachi Chemical in In re Capacitors.
  • Represented cable network company in dispute with big data vendor.
  • Successfully obtained millions of dollars and favorable resolutions for plaintiffs in monopolization claims against competitors, including on behalf of Mylan Pharmaceuticals, Amphastar Pharmaceuticals, and others.
  • Developed and advised on compliance programs for various companies, including global development and construction company, spirits manufacturer and trade association, real estate company, watch manufacturer, electronic component manufacturer, and numerous pharmaceutical companies.
  • Defeated class certification on behalf of Transitions Optical in In re Photochromic Lens.
  • Successfully resolved antitrust claims against Walgreens in Thompson v. 1-800 Contacts.
  • Obtained summary judgment for Netflix in Resnick v. Netflix.
Matters

Representative Matters

  • Defending Mylan Inc. against price-fixing and market allocation claims in one of the largest multi-district litigations, In re Generic Pharmaceuticals, brought by private class and non-class plaintiffs as well as dozens of State AGs.
  • Defending multi-family apartment owner/operator in In re RealPage, cutting-edge litigation brought by putative class of renters regarding algorithmic pricing software.
  • Defending former CEO of healthcare company in alleged no-poach case brought by putative class of employees, In re Outpatient.
  • Defending specialty pharmaceutical manufacturer in alleged sham litigation matter brought by generic competitor.
  • Defending electronic technology company against California unfair competition claim brought by competitor.
  • Defending global tire manufacturer against price-fixing claims brought by putative classes of purchasers in In re Replacement Tires.
  • Defending news agency company against collusion claims.
  • Representing pharmaceutical manufacturers in connection with reverse payment litigations, and obtained dismissals in other such litigations.
  • Successfully resolved price-fixing claims against Hitachi Chemical in In re Capacitors.
  • Represented cable network company in dispute with big data vendor.
  • Successfully obtained millions of dollars and favorable resolutions for plaintiffs in monopolization claims against competitors, including on behalf of Mylan Pharmaceuticals, Amphastar Pharmaceuticals, and others.
  • Developed and advised on compliance programs for various companies, including global development and construction company, spirits manufacturer and trade association, real estate company, watch manufacturer, electronic component manufacturer, and numerous pharmaceutical companies.
  • Defeated class certification on behalf of Transitions Optical in In re Photochromic Lens.
  • Successfully resolved antitrust claims against Walgreens in Thompson v. 1-800 Contacts.
  • Obtained summary judgment for Netflix in Resnick v. Netflix.

Select Publications

  • Co-author, “Labcorp v. Davis Challenge Regarding Uninjured Class Members Dismissed as Improvidently Granted,” Wilson Sonsini Alert, June 11, 2025
  • Co-author, “Enforcement Priorities of President Trump’s DOJ and FTC Begin to Take Shape,” Wilson Sonsini Alert, February 26, 2025
  • Co-author, “Navigating Pharmaceutical Patent Settlements and Reverse Payments: Key Takeaways from the FTC’s Latest MMA Reports,” Wilson Sonsini Alert, January 22, 2025

  • Co-author, “2025 Year in Preview: Trends and Key Decisions in Private Litigation,” Wilson Sonsini Alert, January 16, 2025

  • Co-author, "The Fine Print of Competition: The Use of Jury Instructions in Labor-Related Cases to Modify the Standard of Proof," 8(4) Competition Law and Policy Debate, 2024
  • Co-author, “Latest Ruling Relating to Pricing Software Highlights Antitrust Risks,” Wilson Sonsini Alert, December 9, 2024
  • Co-author, "Antitrust and Labor Issues Around the World: A Comparative Analysis," American Bar Association's Antitrust Magazine, Summer 2022
  • Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, "Seventh Circuit Affirms Denial of Claims Brought Against AbbVie," Wilson Sonsini Alert, August 8, 2022
  • Co-author with N. Mendelsohn, K. O’Rourke, and J. Soven, “Ninth Circuit Limits Ability of Indirect Purchaser Classes to Bring Nationwide Suits,” Wilson Sonsini Alert, October 12, 2021
  • Co-author with S. Chung and J. Jacobson, "Second Circuit Upholds Settlement Agreements Among Competitors Not to Bid on Rivals’ Names as Keywords," Wilson Sonsini Alert, June 14, 2021
  • Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, “Fifth Circuit Upholds Federal Trade Commission Ruling in Impax Laboratories, Inc. v. Federal Trade Commission and Grants Substantial Deference to the FTC,” Wilson Sonsini Alert, April 20, 2021
  • Co-author with M. Rosman and B. Tuyay, "Retaining Ephemeral Messages To Prepare For DOJ Scrutiny," Law360, July 29, 2019
  • Co-author with C. Boylu and B. Coffman, "The Latest Developments in Antitrust Class Certification," Law360, January 30, 2019
  • "U.S.A." chapter, Competition Litigation 2018, Tenth Edition, International Comparative Legal Guide, September 4, 2017
  • "U.S.A." chapter, Competition Litigation 2017, Ninth Edition, International Comparative Legal Guide, September 16, 2016
  • Co-author with S. Silber and B. Coffman, "A Return to Republican Antitrust Policies for Pharma," Law360, January 24, 2017
  • Co-author with S. Silber, C. Armour, K. Kemp, B. Coffman, and R. Maddock, "Pharmaceutical Antitrust Litigation in 2015—Settlements, Product Hopping and REMS," CPI Antitrust Chronicle, Competition Policy International, December 14, 2015
  • Co-author with S. Silber, B. Coffman, and K. Kemp, "Where We Stand On Pharmaceutical Patent Settlements," Law360, October 23, 2015
  • "U.S.A." chapter, Competition Litigation 2016, Eighth Edition, International Comparative Legal Guide, September 25, 2015
  • Co-author with M. Rosman, S. Silber, J. VanHooreweghe, and B. Coffman, "DOJ Investigation into Generic Pharma: You Could Be Next," Law360, March 30, 2015

 

Select Speaking Engagements

  • Panelist, “Challenges in Litigating Civil Cases with Parallel Criminal Investigation,” ABA Cartel and Criminal Practice Panel, June 2021

  • Panelist, “Generics Exclusion: What Conduct Crosses the Lines?” Antitrust in Life Sciences Conference hosted by Concurrences and Fordham Competition Law Institute, July 2020

  • Moderator, “Competition Enforcement of Digital Platforms in the US, Japan and Other Jurisdictions,” New York State Bar Association, Global Conference 2019, Tokyo, Japan

  • Presenter, "Recent Developments in Private Litigation," ABA Corporate Counseling Committee Monthly Antitrust Update, Section of Antitrust Law, February 2019
  • "All Things Vertical: Divergence or Convergence?" Fordham Competition Law Institute 45th Annual Conference on International Antitrust Law and Policy, September 2018
  • "REMS: Are the Federal Agencies Signaling Increased Scrutiny?" American Bar Association Health Care and Pharmaceuticals Committee Panel, June 2018
  • "End the Shenanigans or Business as Usual?: Update on Pharmaceutical Antitrust Issues," New York City Bar Association Antitrust & Trade Regulation Committee, November 2017
  • "Pushing Forward or Staying the Course?: Product Hopping, Exclusionary Conduct, and the Recent Suboxone MTD Ruling," American Bar Association State Enforcement Committee Panel, October 2017
Insights

Select Publications

  • Co-author, “Labcorp v. Davis Challenge Regarding Uninjured Class Members Dismissed as Improvidently Granted,” Wilson Sonsini Alert, June 11, 2025
  • Co-author, “Enforcement Priorities of President Trump’s DOJ and FTC Begin to Take Shape,” Wilson Sonsini Alert, February 26, 2025
  • Co-author, “Navigating Pharmaceutical Patent Settlements and Reverse Payments: Key Takeaways from the FTC’s Latest MMA Reports,” Wilson Sonsini Alert, January 22, 2025

  • Co-author, “2025 Year in Preview: Trends and Key Decisions in Private Litigation,” Wilson Sonsini Alert, January 16, 2025

  • Co-author, "The Fine Print of Competition: The Use of Jury Instructions in Labor-Related Cases to Modify the Standard of Proof," 8(4) Competition Law and Policy Debate, 2024
  • Co-author, “Latest Ruling Relating to Pricing Software Highlights Antitrust Risks,” Wilson Sonsini Alert, December 9, 2024
  • Co-author, "Antitrust and Labor Issues Around the World: A Comparative Analysis," American Bar Association's Antitrust Magazine, Summer 2022
  • Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, "Seventh Circuit Affirms Denial of Claims Brought Against AbbVie," Wilson Sonsini Alert, August 8, 2022
  • Co-author with N. Mendelsohn, K. O’Rourke, and J. Soven, “Ninth Circuit Limits Ability of Indirect Purchaser Classes to Bring Nationwide Suits,” Wilson Sonsini Alert, October 12, 2021
  • Co-author with S. Chung and J. Jacobson, "Second Circuit Upholds Settlement Agreements Among Competitors Not to Bid on Rivals’ Names as Keywords," Wilson Sonsini Alert, June 14, 2021
  • Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, “Fifth Circuit Upholds Federal Trade Commission Ruling in Impax Laboratories, Inc. v. Federal Trade Commission and Grants Substantial Deference to the FTC,” Wilson Sonsini Alert, April 20, 2021
  • Co-author with M. Rosman and B. Tuyay, "Retaining Ephemeral Messages To Prepare For DOJ Scrutiny," Law360, July 29, 2019
  • Co-author with C. Boylu and B. Coffman, "The Latest Developments in Antitrust Class Certification," Law360, January 30, 2019
  • "U.S.A." chapter, Competition Litigation 2018, Tenth Edition, International Comparative Legal Guide, September 4, 2017
  • "U.S.A." chapter, Competition Litigation 2017, Ninth Edition, International Comparative Legal Guide, September 16, 2016
  • Co-author with S. Silber and B. Coffman, "A Return to Republican Antitrust Policies for Pharma," Law360, January 24, 2017
  • Co-author with S. Silber, C. Armour, K. Kemp, B. Coffman, and R. Maddock, "Pharmaceutical Antitrust Litigation in 2015—Settlements, Product Hopping and REMS," CPI Antitrust Chronicle, Competition Policy International, December 14, 2015
  • Co-author with S. Silber, B. Coffman, and K. Kemp, "Where We Stand On Pharmaceutical Patent Settlements," Law360, October 23, 2015
  • "U.S.A." chapter, Competition Litigation 2016, Eighth Edition, International Comparative Legal Guide, September 25, 2015
  • Co-author with M. Rosman, S. Silber, J. VanHooreweghe, and B. Coffman, "DOJ Investigation into Generic Pharma: You Could Be Next," Law360, March 30, 2015

 

Select Speaking Engagements

  • Panelist, “Challenges in Litigating Civil Cases with Parallel Criminal Investigation,” ABA Cartel and Criminal Practice Panel, June 2021

  • Panelist, “Generics Exclusion: What Conduct Crosses the Lines?” Antitrust in Life Sciences Conference hosted by Concurrences and Fordham Competition Law Institute, July 2020

  • Moderator, “Competition Enforcement of Digital Platforms in the US, Japan and Other Jurisdictions,” New York State Bar Association, Global Conference 2019, Tokyo, Japan

  • Presenter, "Recent Developments in Private Litigation," ABA Corporate Counseling Committee Monthly Antitrust Update, Section of Antitrust Law, February 2019
  • "All Things Vertical: Divergence or Convergence?" Fordham Competition Law Institute 45th Annual Conference on International Antitrust Law and Policy, September 2018
  • "REMS: Are the Federal Agencies Signaling Increased Scrutiny?" American Bar Association Health Care and Pharmaceuticals Committee Panel, June 2018
  • "End the Shenanigans or Business as Usual?: Update on Pharmaceutical Antitrust Issues," New York City Bar Association Antitrust & Trade Regulation Committee, November 2017
  • "Pushing Forward or Staying the Course?: Product Hopping, Exclusionary Conduct, and the Recent Suboxone MTD Ruling," American Bar Association State Enforcement Committee Panel, October 2017
Focus Areas
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust and Competition
  • Antitrust and Intellectual Property
  • Federal Trade Commission
  • Third-Party Merger and Non-Merger Antitrust Representation
Recent Insights
News Articles
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Learn More
Client Highlights
Court Denies Plaintiffs Leave to Amend in Replacement Tires Antitrust MDL, Dismissing Alleged Price-Fixing Cases with Prejudice
A Wilson Sonsini team recently obtained a full dismissal with prejudice on behalf of Continental Aktiengesellschaft and Continental Tire the Americas, LLC of alleged price-fixing claims on replacement tires. 
Learn More
View All
Recent Events
Speaking Engagements
PLI Class Action Litigation 2023
The Practising Law Institute (PLI) hosts their Class Action Litigation 2023 program live from New York (with streaming option available). This program will benefit attorneys who are prosecuting or defending class action cases as well as in-house counsel who want to gain a competitive edge in this fast-moving field.  Wilson Sonsini Antitrust partner Jeffrey C. Bank provides his expertise, joining the program’s panel on Litigation Strategies for Class Action Practice. CLE credit available. Learn more and register here.
Learn More
Affiliated Programs
Life Sciences Antitrust Conference
As we proceed through 2021, the spotlight on antitrust activity in the life sciences industry shines brighter than ever. For several years, state and federal antitrust enforcers in the U.S. and even international antitrust and competition authorities have been watching the life sciences industry closely for anticompetitive activity. The Biden Administration is now forming its new competition policy and there is pending antitrust legislation which will unquestionably affect the life sciences industries. At the same time, the U.S. DOJ has just confirmed that they are developing new policies to prevent patents from being used as tools for anticompetitive practices, a recent series of criminal antitrust investigations have been brought by federal and state authorities alleging generic price fixing collusion, and a novel multinational task force has just been put in place to examine the anticompetitive impact of life sciences M+A activity. All of these new changes are raising life sciences antitrust concerns to an all-time high, and could significantly increase the volume of litigation for IP and antitrust trial lawyers and their clients.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.